Literature DB >> 23958558

Should we lower lipids in nonalcoholic fatty liver disease?

Geoffrey Farrell1.   

Abstract

Entities:  

Keywords:  3-hydroxy-3-methylglutaryl–coenzyme A; ALT; FC; GREACE; Greek Artorvastatin and Coronary Heart Disease Evaluation; HDL; HMGCoA; LDL; NAFLD; NASH; T2D; alanine aminotransferase; free cholesterol; high-density lipoprotein; low-density lipoprotein; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; type 2 diabetes

Mesh：

Substances：

Year:  2013        PMID： 23958558     DOI： 10.1016/j.cgh.2013.07.041

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  5 in total

1.  Nonalcoholic Fatty Liver Disease: An Important Consideration for Primary Care Providers in Hawai'i.

Authors:  Robert J Pattison; James Phillip Esteban; Tomoki Sempokuya; Jakrin Kewcharoen; Sumodh Kalathil; Scott K Kuwada
Journal:  Hawaii J Health Soc Welf       Date:  2020-06-01

2.  Managing non-alcoholic fatty liver disease.

Authors:  Jing Hieng Ngu; George Boon Bee Goh; Zhongxian Poh; Roy Soetikno
Journal:  Singapore Med J       Date:  2016-07       Impact factor: 1.858

3.  The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.

Authors:  Tracey G Simon; Kathleen E Corey; Christopher P Cannon; Michael Blazing; Jeong-Gun Park; Michelle L O'Donoghue; Raymond T Chung; Robert P Giugliano
Journal:  Int J Cardiol       Date:  2018-05-26       Impact factor: 4.164

Review 4.  P2X7 receptor as a key player in oxidative stress-driven cell fate in nonalcoholic steatohepatitis.

Authors:  Saurabh Chatterjee; Suvarthi Das
Journal:  Oxid Med Cell Longev       Date:  2015-03-01       Impact factor: 6.543

5.  Medications in type-2 diabetics and their association with liver fibrosis.

Authors:  Mohamed Tausif Siddiqui; Hina Amin; Rajat Garg; Pravallika Chadalavada; Wael Al-Yaman; Rocio Lopez; Amandeep Singh
Journal:  World J Gastroenterol       Date:  2020-06-21       Impact factor: 5.742
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.